[en] X-linked hypophosphatemia (XLH) is the most common genetic form of hypophosphatemic rickets and osteomalacia. In this disease, mutations in the PHEX gene lead to elevated levels of the hormone fibroblast growth factor 23 (FGF23), resulting in renal phosphate wasting and impaired skeletal and dental mineralization. Recently, international guidelines for the diagnosis and treatment of this condition have been published. However, more specific recommendations are needed to provide guidance at the national level, considering resource availability and health economic aspects. A national multidisciplinary group of Belgian experts convened to discuss translation of international best available evidence into locally feasible consensus recommendations. Patients with XLH may present to a wide array of primary, secondary and tertiary care physicians, among whom awareness of the disease should be raised. XLH has a very broad differential-diagnosis for which clinical features, biochemical and genetic testing in centers of expertise are recommended. Optimal care requires a multidisciplinary approach, guided by an expert in metabolic bone diseases and involving (according to the individual patient’s needs) pediatric and adult medical specialties and paramedical caregivers, including but not limited to general practitioners, dentists, radiologists and orthopedic surgeons. In children with severe or refractory symptoms, FGF23 inhibition using burosumab may provide superior outcomes compared to conventional medical therapy with phosphate supplements and active vitamin D analogues. Burosumab has also demonstrated promising results in adults on certain clinical outcomes such as pseudofractures. In summary, this work outlines recommendations for clinicians and policymakers, with a vision for improving the diagnostic and therapeutic landscape for XLH patients in Belgium.
Disciplines :
Orthopedics, rehabilitation & sports medicine General & internal medicine
Author, co-author :
Laurent, Michaël
De Schepper, Jan
Trouet, Dominique
Godefroid, Nathalie
Boros, Emese
Heinrichs, Claudine
Bravenboer, Bert
Velkeniers, Brigitte
Lammens, Johan
Harvengt, Pol
Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Kaux, Jean-François ; Université de Liège - ULiège > Département des sciences de la motricité > Médecine physique, réadaptation et traumatologie du sport
LOMBET, Jacques ; Centre Hospitalier Universitaire de Liège - CHU > Département de Pédiatrie > Service de pédiatrie
Hawley S, Shaw NJ, Delmestri A, Prieto-Alhambra D, Cooper C, Pinedo-Villanueva R, et al. Prevalence and Mortality of Individuals With X-LinkedHypophosphatemia: A United Kingdom Real-World Data Analysis. J ClinEndocrinol Metab (2020) 105(3):e871–8. doi: 10.1210/clinem/dgz203
Rafaelsen S, Johansson S, Raeder H, Bjerknes R. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol (2016) 174(2):125–36. doi: 10.1530/EJE-15-0515
Vlaams Agentschap Zorg en Gezondheid. Oprichting Vlaams Netwerk Zeldzame Ziekten. Vlaams Agentschap Zorg en Gezondheid (2017). Available at: https://www.zorg-en-gezondheid.be/oprichting-vlaams-netwerk-zeldzame-ziekten.
Bacchetta J, Bardet C, Prie D. Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting. Metabolism (2020) 103S:153865. doi: 10.1016/j.metabol.2019.01.006
Gohil A, Imel EA. FGF23 and Associated Disorders of Phosphate Wasting. Pediatr Endocrinol Rev (2019) 17(1):17–34. doi: 10.17458/per.vol17.2019.gi.fgf23anddisordersphosphate
Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis (2019) 14(1):58. doi: 10.1186/s13023-019-1014-8
Mindler GT, Kranzl A, Stauffer A, Haeusler G, Ganger R, Raimann A. Disease-specific gait deviations in pediatric patients with X-linked hypophosphatemia. Gait Posture (2020) 81:78–84. doi: 10.1016/j.gaitpost.2020.07.007
Veilleux LN, Cheung MS, Glorieux FH, Rauch F. The muscle-bone relationship in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab (2013) 98(5):E990–5. doi: 10.1210/jc.2012-4146
Veilleux LN, Cheung M, Ben Amor M, Rauch F. Abnormalities in muscle density and muscle function in hypophosphatemic rickets. J Clin Endocrinol Metab (2012) 97(8):E1492–8. doi: 10.1210/jc.2012-1336
Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician’s guide to X-linkedhypophosphatemia. J Bone Miner Res (2011) 26(7):1381–8. doi: 10.1002/jbmr.340
Ferizovic N, Marshall J, Williams AE, Mughal MZ, Shaw N, Mak C, et al. Exploring the Burden of X-Linked Hypophosphataemia: An OpportunisticQualitative Study of Patient Statements Generated During a Technology Appraisal. Adv Ther (2020) 37(2):770–84. doi: 10.1007/s12325-019-01193-0
Seefried L, Smyth M, Keen R, Harvengt P. Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. Osteoporos Int (2021) 32(1):7–22. doi: 10.1007/s00198-020-05548-0
Berndt M, Ehrich JH, Lazovic D, Zimmermann J, Hillmann G, Kayser C, et al. Clinical course of hypophosphatemic rickets in 23 adults. Clin Nephrol (1996) 45(1):33–41.
Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, et al. Impaired quality of life in adults with X-linked hypophosphatemiaand skeletal symptoms. Eur J Endocrinol (2016) 174(3):325–33. doi: 10.1530/EJE-15-0661
Lecoq AL, Brandi ML, Linglart A, Kamenicky P. Management of X-linked hypophosphatemia in adults. Metabolism (2020) 103S:154049. doi: 10.1016/j.metabol.2019.154049
Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, et al. The Lifelong Impact of X-Linked Hypophosphatemia: Results From aBurden of Disease Survey. J Endocr Soc (2019) 3(7):1321–34. doi: 10.1210/js.2018-00365
Hughes M, Macica C, Meriano C, Doyle M. Giving Credence to the Experience of X-Linked Hypophosphatemia inAdulthood: An Interprofessional Mixed-Methods Study. J Patient Cent ResRev (2020) 7(2):176–88. doi: 10.17294/2330-0698.1727
Nehgme R, Fahey JT, Smith C, Carpenter TO. Cardiovascular abnormalities in patients with X-linkedhypophosphatemia. J Clin Endocrinol Metab (1997) 82(8):2450–4. doi: 10.1210/jcem.82.8.4181
Alon US, Monzavi R, Lilien M, Rasoulpour M, Geffner ME, Yadin O. Hypertension in hypophosphatemic rickets–role of secondaryhyperparathyroidism. Pediatr Nephrol (2003) 18(2):155–8. doi: 10.1007/s00467-002-1044-6
Zhukouskaya VV, Rothenbuhler A, Colao A, Di Somma C, Kamenicky P, Trabado S, et al. Increased prevalence of overweight and obesity in children withX-linked hypophosphatemia. Endocr Connect (2020) 9(2):144–53. doi: 10.1530/EC-19-0481
Hawley S, Shaw NJ, Delmestri A, Prieto-Alhambra D, Cooper C, Pinedo-Villanueva R, et al. Higher prevalence of non-skeletal comorbidity related to X-linkedhypophosphataemia: a UK parallel cohort study using CPRD. Rheumatol (Oxford) (2020). doi: 10.1093/rheumatology/keaa859
Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and managementof X-linked hypophosphataemia. Nat Rev Nephrol (2019) 15(7):435–55. doi: 10.1038/s41581-019-0152-5
Padidela R, Cheung MS, Saraff V, Dharmaraj P. Clinical guidelines for burosumab in the treatment of XLH inchildren and adolescents: British paediatric and adolescent bone grouprecommendations. Endocr Connect (2020) 9(10):1051–6. doi: 10.1530/EC-20-0291
Mao M, Carpenter TO, Whyte MP, Skrinar A, Chen CY, San Martin J, et al. Growth Curves for Children with X-linkedHypophosphatemia. J Clin Endocrinol Metab (2020) 105(10):3243–9. doi: 10.1210/clinem/dgaa495
Duncanson GO, Worth HG. Pseudohypophosphataemia as a result of bilirubin interference. Ann Clin Biochem (1990) 27(Pt 3):253–7.doi: 10.1177/000456329002700312
Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, et al. Rationale and Approaches to Phosphate and Fibroblast Growth Factor23 Reduction in CKD. J Am Soc Nephrol (2015) 26(10):2328–39. doi: 10.1681/ASN.2015020117
Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose onHypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA (2020) 323(5):432–43. doi: 10.1001/jama.2019.22450
Tiosano D, Hochberg Z. Hypophosphatemia: the common denominator of allrickets. J Bone Miner Metab (2009) 27(4):392–401. doi: 10.1007/s00774-009-0079-1
Sabbagh Y, Carpenter TO, Demay MB. Hypophosphatemia leads to rickets by impairing caspase-mediatedapoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci U S A(2005) 102(27):9637–42. doi: 10.1073/pnas.0502249102
Seikaly M, Browne R, Baum M. Nephrocalcinosis is associated with renal tubular acidosis in children with X-linked hypophosphatemia. Pediatrics (1996) 97(1):91–3.
Malhotra R, Guleria P, Barwad A, Pramanik R, Tandon N. A unique case of light chain (AL) amyloidosis masquerading ashypophosphatemic osteomalacia. Osteoporos Int (2021) 32(2):387–92. doi: 10.1007/s00198-020-05622-7
Cebeci AN, Zou M, BinEssa HA, Alzahrani AS, Al-Rijjal RA, Al-Enezi AF, et al. Mutation of SGK3, a Novel Regulator of Renal Phosphate Transport,Causes Autosomal Dominant Hypophosphatemic Rickets. J Clin EndocrinolMetab (2020) 105(6):1840–50. doi: 10.1210/clinem/dgz260
Witteveen JE, van Lierop AH, Papapoulos SE, Hamdy NA. Increased circulating levels of FGF23: an adaptive response inprimary hyperparathyroidism? Eur J Endocrinol (2012) 166(1):55–60. doi: 10.1530/EJE-11-0523
Nilsson IL, Norenstedt S, Granath F, Zedenius J, Pernow Y, Larsson TE. FGF23, metabolic risk factors, and blood pressure in patients withprimary hyperparathyroidism undergoing parathyroid adenomectomy. Surgery (2016) 159(1):211–7. doi: 10.1016/j.surg.2015.06.057
Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mousemodel of primary hyperparathyroidism. J Am Soc Nephrol (2007) 18(10):2683–8. doi: 10.1681/ASN.2006070783
Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, et al. Fibroblast growth factor 23 inhibits extrarenal synthesis of1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res (2013) 28(1):46–55. doi: 10.1002/jbmr.1740
Bai X, Miao D, Xiao S, Qiu D, St-Arnaud R, Petkovich M, et al. CYP24 inhibition as a therapeutic target in FGF23-mediated renalphosphate wasting disorders. J Clin Invest (2016) 126(2):667–80. doi: 10.1172/JCI81928
Lecoq AL, Chaumet-Riffaud P, Blanchard A, Dupeux M, Rothenbuhler A, Lambert B, et al. Hyperparathyroidism in Patients With X-LinkedHypophosphatemia. J Bone Miner Res (2020) 35(7):1263–73. doi: 10.1002/jbmr.3992
DeLacey S, Liu Z, Broyles A, El-Azab SA, Guandique CF, James BC, et al. Hyperparathyroidism and parathyroidectomy in X-linkedhypophosphatemia patients. Bone (2019) 127:386–92. doi: 10.1016/j.bone.2019.06.025
Saito H, Noda H, Gatault P, Bockenhauer D, Loke KY, Hiort O, et al. Progression of Mineral Ion Abnormalities in Patients With JansenMetaphyseal Chondrodysplasia. J Clin Endocrinol Metab (2018) 103(7):2660–9. doi: 10.1210/jc.2018-00332
Liu C, Zhao Z, Wang O, Li M, Xing X, Hsieh E, et al. Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of theLiterature. Calcif Tissue Int (2019) 105(5):476–86. doi: 10.1007/s00223-019-00597-y
Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ. Iron modifies plasma FGF23 differently in autosomal dominanthypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab (2011) 96(11):3541–9. doi: 10.1210/jc.2011-1239
Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, et al. Iron deficiency drives an autosomal dominant hypophosphatemicrickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A (2011) 108(46):E1146–55. doi: 10.1073/pnas.1110905108
Imel EA, Gray AK, Padgett LR, Econs MJ. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia. Bone (2014) 60:87–92. doi: 10.1016/j.bone.2013.12.001
Kapelari K, Kohle J, Kotzot D, Hogler W. Iron Supplementation Associated With Loss of Phenotype in Autosomal Dominant Hypophosphatemic Rickets. J Clin Endocrinol Metab (2015) 100(9):3388–92. doi: 10.1210/jc.2015-2391
Imel EA, Liu Z, Coffman M, Acton D, Mehta R, Econs MJ. Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets. J Bone Miner Res (2020) 35(2):231–8. doi: 10.1002/jbmr.3878
Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res (2013) 28(8):1793–803. doi: 10.1002/jbmr.1923
Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-inducedhypophosphatemia. JCI Insight (2018) 3(23):e124486. doi: 10.1172/jci.insight.124486
Saeedi R, Jiang SY, Holmes DT, Kendler DL. Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia. Calcif Tissue Int (2014) 94(6):665–8. doi: 10.1007/s00223-014-9854-7
Saito T, Shimizu Y, Hori M, Taguchi M, Igarashi T, Fukumoto S, et al. A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone (2011) 49(4):913–6. doi: 10.1016/j.bone.2011.06.029
Guirado E, Chen Y, Ross RD, Zhang Y, Chaussain C, George A. Disrupted Protein Expression and Altered Proteolytic Events in Hypophosphatemic Dentin Can Be Rescued by Dentin Matrix Protein 1. Front Physiol (2020) 11:82. doi: 10.3389/fphys.2020.00082
Kotwal A, Ferrer A, Kumar R, Singh RJ, Murthy V, Schultz-Rogers L, et al. Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations. J Bone Miner Res (2020) 35(4):662–70. doi: 10.1002/jbmr.3938
Oheim R, Zimmerman K, Maulding ND, Sturznickel J, von Kroge S, Kavanagh D, et al. Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency. J Bone Miner Res (2020) 35(3):528–39. doi: 10.1002/jbmr.3911
Ferreira CR, Hackbarth ME, Ziegler SG, Pan KS, Roberts MS, Rosing DR, et al. Prospective phenotyping of long-term survivors of generalizedarterial calcification of infancy (GACI). Genet Med (2021) 23(2):396–407. doi: 10.1038/s41436-020-00983-0
Brachet C, Mansbach AL, Clerckx A, Deltenre P, Heinrichs C. Hearing loss is part of the clinical picture of ENPP1 loss of function mutation. Horm Res Paediatr (2014) 81(1):63–6. doi: 10.1159/000354661
Staretz-Chacham O, Shukrun R, Barel O, Pode-Shakked B, Pleniceanu O, Anikster Y, et al. Novel homozygous ENPP1 mutation causes generalized arterial calcifications of infancy, thrombocytopenia, and cardiovascular and central nervous system syndrome. Am J Med Genet A (2019) 179(10):2112–8. doi: 10.1002/ajmg.a.61334
Whyte MP, Amalnath SD, McAlister WH, McKee MD, Veis DJ, Huskey M, et al. Hypophosphatemic osteosclerosis, hyperostosis, and enthesopathy associated with novel homozygous mutations of DMP1 encoding dentin matrix protein 1 and SPP1 encoding osteopontin: The first digenic SIBLING protein osteopathy? Bone (2020) 132:115190. doi: 10.1016/j.bone.2019.115190
Brownstein CA, Adler F, Nelson-Williams C, Iijima J, Li P, Imura A, et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A (2008) 105(9):3455–60. doi: 10.1073/pnas.0712361105
Tagliabracci VS, Engel JL, Wiley SE, Xiao J, Gonzalez DJ, Nidumanda Appaiah H, et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci U S A (2014) 111(15):5520–5. doi: 10.1073/pnas.1402218111
de Las Rivas M, Paul Daniel EJ, Narimatsu Y, Companon I, Kato K, Hermosilla P, et al. Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3. Nat Chem Biol (2020) 16(3):351–60. doi: 10.1038/s41589-019-0444-x
Takashi Y, Kosako H, Sawatsubashi S, Kinoshita Y, Ito N, Tsoumpra MK, et al. Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. Proc Natl Acad Sci U S A (2019) 116(23):11418–27. doi: 10.1073/pnas.1815166116
Takeyari S, Yamamoto T, Kinoshita Y, Fukumoto S, Glorieux FH, Michigami T, et al. Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome. Bone (2014) 67:56–62. doi: 10.1016/j.bone.2014.06.026
Acevedo AC, Poulter JA, Alves PG, de Lima CL, Castro LC, Yamaguti PM, et al. Variability of systemic and oro-dental phenotype in two families with non-lethal Raine syndrome with FAM20C mutations. BMC Med Genet (2015) 16:8. doi: 10.1186/s12881-015-0154-5
Rolvien T, Kornak U, Schinke T, Amling M, Oheim R. A novel FAM20C mutation causing hypophosphatemic osteomalacia withosteosclerosis (mild Raine syndrome) in an elderly man with spontaneous osteonecrosis of theknee. Osteoporos Int (2019) 30(3):685–9. doi: 10.1007/s00198-018-4667-6
Whyte MP, McAlister WH, Fallon MD, Pierpont ME, Bijanki VN, Duan S, et al. Raine Syndrome (OMIM #259775), Caused By FAM20C Mutation, IsCongenital Sclerosing Osteomalacia With Cerebral Calcification (OMIM 259660). J Bone Miner Res (2017) 32(4):757–69. doi: 10.1002/jbmr.3034
Roberts MS, Burbelo PD, Egli-Spichtig D, Perwad F, Romero CJ, Ichikawa S, et al. Autoimmune hyperphosphatemic tumoral calcinosis in a patient withFGF23 autoantibodies. J Clin Invest (2018) 128(12):5368–73. doi: 10.1172/JCI122004
Dauchez A, Souffir C, Quartier P, Baujat G, Briot K, Roux C. Hyperphosphatemic Familial Tumoral Calcinosis With Galnt3 Mutation:Transient Response to Anti-Interleukin-1 Treatments. JBMR Plus (2019) 3(7):e10185. doi: 10.1002/jbm4.10185
Jiang Y, Xia WB, Xing XP, Silva BC, Li M, Wang O, et al. Tumor-induced osteomalacia: an important cause of adult-onsethypophosphatemic osteomalacia in China: Report of 39 cases and review of theliterature. J Bone Miner Res (2012) 27(9):1967–75. doi: 10.1002/jbmr.1642
Imanishi Y, Hashimoto J, Ando W, Kobayashi K, Ueda T, Nagata Y, et al. Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia. J Bone Miner Metab (2012) 30(1):93–9. doi: 10.1007/s00774-011-0290-8
Hoffman WH, Jain A, Chen H, Fedarko NS. Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome. Am J Med Genet A (2008) 146A(16):2164–8. doi: 10.1002/ajmg.a.32395
Kuthiroly S, Yesodharan D, Ghosh A, White KE, Nampoothiri S. Osteoglophonic Dysplasia: Phenotypic and Radiological Clues. J Pediatr Genet (2017) 6(4):247–51. doi: 10.1055/s-0037-1602816
Zeger MD, Adkins D, Fordham LA, White KE, Schoenau E, Rauch F, et al. Hypophosphatemic rickets in opsismodysplasia. J Pediatr Endocrinol Metab (2007) 20(1):79–86. doi: 10.1515/JPEM.2007.20.1.79
Laurent MR, Bravenboer N, Van Schoor NM, Bouillon R, Pettifor JM, Lips P. Rickets and Osteomalacia. In: Bilezikian JP, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Ninth Edition. Hoboken, NJ, USA: American Society for Bone and Mineral Research (2018). p. 684–94.
Rosalki SB, Foo AY, Burlina A, Prellwitz W, Stieber P, Neumeier D, et al. Multicenter evaluation of Iso-ALP test kit for measurement of bone alkaline phosphatase activity in serum and plasma. Clin Chem (1993) 39(4):648–52. doi: 10.1093/clinchem/39.4.648
Bouman AA, de Ridder CM, Nijhof JH, Netelenbos JC, Delemarre-vd Waal HA. Immunoadsorption assay for bone alkaline phosphatase compared with wheat germ agglutinin precipitation assay in serum from (pre)pubertal girls. Clin Chem (1996) 42(12):1970–4.
Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphateconcentration. Lancet (1975) 2(7929):309–10. doi: 10.1016/s0140-6736(75)92736-1
Payne RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications andinterpretation. Ann Clin Biochem (1998) 35(Pt 2):201–6. doi: 10.1177/000456329803500203
Imel EA. Congenital Conditions of Hypophosphatemia inChildren. Calcif Tissue Int (2021) 108(1):74–90. doi: 10.1007/s00223-020-00692-5
Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-four-hour urine chemistries and the risk of kidney stonesamong women and men. Kidney Int (2001) 59(6):2290–8. doi: 10.1046/j.1523-1755.2001.00746.x
Pak CY, Sakhaee K, Moe OW, Poindexter J, Adams-Huet B, Pearle MS, et al. Defining hypercalciuria in nephrolithiasis. Kidney Int (2011) 80(7):777–82. doi: 10.1038/ki.2011.227
So NP, Osorio AV, Simon SD, Alon US. Normal urinary calcium/creatinine ratios in African-American andCaucasian children. Pediatr Nephrol (2001) 16(2):133–9. doi: 10.1007/s004670000510
Metz MP. Determining urinary calcium/creatinine cut-offs for the paediatricpopulation using published data. Ann Clin Biochem (2006) 43(Pt 5):398–401. doi: 10.1258/00045630677852010
Goldfarb DS. Metabolic Investigations: When and in Whom. In: Rao N, PG, Kavanagh J, editors. Urinary Tract Stone Disease. London: Springer (2010). p. 659–65.
Higgins V, Truong D, White-Al Habeeb NMA, Fung AWS, Hoffman B, Adeli K. Pediatric reference intervals for 1,25-dihydroxyvitamin D using theDiaSorin LIAISON XL assay in the healthy CALIPER cohort. Clin Chem LabMed (2018) 56(6):964–72. doi: 10.1515/cclm-2017-0767
Vanderschueren D, Pye SR, O’Neill TW, Lee DM, Jans I, Billen J, et al. Active vitamin D (1,25-dihydroxyvitamin D) and bone health inmiddle-aged and elderly men: the European Male Aging Study (EMAS). J ClinEndocrinol Metab (2013) 98(3):995–1005. doi: 10.1210/jc.2012-2772
Smith ER, Cai MM, McMahon LP, Holt SG. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab (2012) 97(9):3357–65. doi: 10.1210/jc.2012-1811
Heijboer AC, Levitus M, Vervloet MG, Lips P, ter Wee PM, Dijstelbloem HM, et al. Determination of fibroblast growth factor 23. Ann Clin Biochem (2009) 46(Pt 4):338–40. doi: 10.1258/acb.2009.009066
Dirks NF, Smith ER, van Schoor NM, Vervloet MG, Ackermans MT, de Jonge R, et al. Pre-analytical stability of FGF23 with the contemporary immunoassays. Clin Chim Acta (2019) 493:104–6. doi: 10.1016/j.cca.2019.02.032
El-Maouche D, Dumitrescu CE, Andreopoulou P, Gafni RI, Brillante BA, Bhattacharyya N, et al. Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type. Osteoporos Int (2016) 27(7):2345–53. doi: 10.1007/s00198-016-3543-5
Souberbielle JC, Prié D, Piketty ML, Rothenbuhler A, Delanaye P, Chanson P, et al. Evaluation of a New Fully Automated Assay for Plasma Intact FGF23. Calcif Tissue Int (2017) 101(5):510–8. doi: 10.1007/s00223-017-0307-y
Piketty ML, Brabant S, Souberbielle JC, Maruani G, Audrain C, Rothenbuhler A, et al. FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference. Clin Chem Lab Med (2020) 58(11):e267–e9. doi: 10.1515/cclm-2020-0460
Cavalier E, Lukas P, Bottani M, Aarsand AK, Ceriotti F, Coskun A, et al. European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of beta-isomerized C-terminal telopeptide of type I collagen (beta-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism. Osteoporos Int (2020) 31(8):1461–70. doi: 10.1007/s00198-020-05362-8
Melhem E, Assi A, El Rachkidi R, Ghanem I. EOS((R)) biplanar X-ray imaging: concept, developments, benefits, and limitations. J Child Orthop (2016) 10(1):1–14. doi: 10.1007/s11832-016-0713-0
Thacher TD, Pettifor JM, Tebben PJ, Creo AL, Skrinar A, Mao M, et al. Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score. Bone (2019) 122:76–81. doi: 10.1016/j.bone.2019.02.010
Van de Wiele C, Dierckx RA, Weynants L, Simons M, Kaufman JM. Whole-body bone scan findings in X-linked hypophosphatemia. Clin Nucl Med (1996) 21(6):483. doi: 10.1097/00003072-199606000-00013
Raimann A, Mehany SN, Feil P, Weber M, Pietschmann P, Boni-Mikats A, et al. Decreased Compressional Sound Velocity Is an Indicator for Compromised Bone Stiffness in X-Linked Hypophosphatemic Rickets (XLH). Front Endocrinol (Lausanne) (2020) 11:355. doi: 10.3389/fendo.2020.00355
Chong WH, Andreopoulou P, Chen CC, Reynolds J, Guthrie L, Kelly M, et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res (2013) 28(6):1386–98. doi: 10.1002/jbmr.1881
Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone (2014) 64:222–7. doi: 10.1016/j.bone.2014.04.016
El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-Delisle C, Merkel R, et al. (68)Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia. J Clin Endocrinol Metab (2016) 101(10):3575–81. doi: 10.1210/jc.2016-2052
Whyte MP, Schranck FW, Armamento-Villareal R. X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab (1996) 81(11):4075–80. doi: 10.1210/jcem.81.11.8923863
Zhang C, Zhao Z, Sun Y, Xu L, JiaJue R, Cui L, et al. Clinical and genetic analysis in a large Chinese cohort of patientswith X-linked hypophosphatemia. Bone (2019) 121:212–20. doi: 10.1016/j.bone.2019.01.021
Ichikawa S, Gray AK, Bikorimana E, Econs MJ. Dosage effect of a Phex mutation in a murine model of X-linkedhypophosphatemia. Calcif Tissue Int (2013) 93(2):155–62. doi: 10.1007/s00223-013-9736-4
Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, et al. Outcome of adult patients with X-linked hypophosphatemia caused byPHEX gene mutations. J Inherit Metab Dis (2018) 41(5):865–76. doi: 10.1007/s10545-018-0147-6
Pronicka E, Popowska E, Rowinska E, Arasimowicz E, Syczewska M, Jurkiewicz D, et al. Anthropometric characteristics of X-linkedhypophosphatemia. Am J Med Genet A (2004) 126A(2):141–9. doi: 10.1002/ajmg.a.20572
Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K, Brock-Jacobsen B, Poulsen MR, et al. Phenotype presentation of hypophosphatemic rickets inadults. Calcif Tissue Int (2010) 87(2):108–19. doi: 10.1007/s00223-010-9373-0
Gjorup H, Kjaer I, Sonnesen L, Haubek D, Beck-Nielsen SS, Hintze H, et al. Craniofacial morphology in patients with hypophosphatemic rickets: a cephalometric study focusing on differences between bone of cartilaginous and intramembranous origin. Am J Med Genet A (2011) 155A(11):2654–60. doi: 10.1002/ajmg.a.34242
Ichikawa S, Traxler EA, Estwick SA, Curry LR, Johnson ML, Sorenson AH, et al. Mutational survey of the PHEX gene in patients with X-linked hypophosphatemic rickets. Bone (2008) 43(4):663–6. doi: 10.1016/j.bone.2008.06.002
Mumm S, Huskey M, Cajic A, Wollberg V, Zhang F, Madson KL, et al. PHEX 3’-UTR c.*231A>G near the polyadenylation signal is a relatively common, mild, American mutation that masquerades as sporadic or X-linked recessive hypophosphatemic rickets. J Bone Miner Res (2015) 30(1):137–43. doi: 10.1002/jbmr.2307
Smith PS, Gottesman GS, Zhang F, Cook F, Ramirez B, Wenkert D, et al. X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3’-UTR Mutation c.*231A>G (A Retrospective Case-Control Study). J Bone Miner Res (2020) 35(5):920–31. doi: 10.1002/jbmr.3955
Zheng B, Wang C, Chen Q, Che R, Sha Y, Zhao F, et al. Functional Characterization of PHEX Gene Variants in Children With X-Linked Hypophosphatemic Rickets Shows No Evidence of Genotype-Phenotype Correlation. J Bone Miner Res (2020) 35(9):1718–25. doi: 10.1002/jbmr.4035
Gaucher C, Walrant-Debray O, Nguyen TM, Esterle L, Garabedian M, Jehan F. PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. Hum Genet (2009) 125(4):401–11. doi: 10.1007/s00439-009-0631-z
Beck-Nielsen SS, Brixen K, Gram J, Brusgaard K. Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets. J Hum Genet (2012) 57(7):453–8. doi: 10.1038/jhg.2012.56
Capelli S, Donghi V, Maruca K, Vezzoli G, Corbetta S, Brandi ML, et al. Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets. Bone (2015) 79:143–9. doi: 10.1016/j.bone.2015.05.040
Christie PT, Harding B, Nesbit MA, Whyte MP, Thakker RV. X-linked hypophosphatemia attributable to pseudoexons of the PHEX gene. J Clin Endocrinol Metab (2001) 86(8):3840–4. doi: 10.1210/jcem.86.8.7730
Thiele S, Werner R, Stubbe A, Hiort O, Hoeppner W. Validation of a next-generation sequencing (NGS) panel to improve the diagnosis of X-linked hypophosphataemia (XLH) and other genetic disorders of renal phosphate wasting. Eur J Endocrinol (2020) 183(5):497–504. doi: 10.1530/EJE-20-0275
Lin Y, Xu J, Li X, Sheng H, Su L, Wu M, et al. Novel variants and uncommon cases among southern Chinese children with X-linked hypophosphatemia. J Endocrinol Invest (2020) 43(11):1577–90. doi: 10.1007/s40618-020-01240-6
Ruppe MD, Brosnan PG, Au KS, Tran PX, Dominguez BW, Northrup H. Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets. Clin Endocrinol (Oxf) (2011) 74(3):312–8. doi: 10.1111/j.1365-2265.2010.03919.x
Kinoshita Y, Saito T, Shimizu Y, Hori M, Taguchi M, Igarashi T, et al. Mutational analysis of patients with FGF23-related hypophosphatemic rickets. Eur J Endocrinol (2012) 167(2):165–72. doi: 10.1530/EJE-12-0071
Raimann A, Mindler GT, Kocijan R, Bekes K, Zwerina J, Haeusler G, et al. Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives. Wien Med Wochenschr (2020) 170(5-6):116–23. doi: 10.1007/s10354-019-00732-2
Lo SH, Lachmann R, Williams A, Piglowska N, Lloyd AJ. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. Qual Life Res (2020) 29(7):1883–93. doi: 10.1007/s11136-020-02465-x
Pecourneau V, Degboe Y, Barnetche T, Cantagrel A, Constantin A, Ruyssen-Witrand A. Effectiveness of Exercise Programs in Ankylosing Spondylitis: A Meta-Analysis of Randomized Controlled Trials. Arch Phys Med Rehabil (2018) 99(2):383–9 e1. doi: 10.1016/j.apmr.2017.07.015
Millner JR, Barron JS, Beinke KM, Butterworth RH, Chasle BE, Dutton LJ, et al. Exercise for ankylosing spondylitis: An evidence-based consensus statement. Semin Arthritis Rheum (2016) 45(4):411–27. doi: 10.1016/j.semarthrit.2015.08.003
Rausch Osthoff AK, Niedermann K, Braun J, Adams J, Brodin N, Dagfinrud H, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis (2018) 77(9):1251–60. doi: 10.1136/annrheumdis-2018-213585
Steele A, Gonzalez R, Garbalosa JC, Steigbigel K, Grgurich T, Parisi EJ, et al. Osteoarthritis, Osteophytes, and Enthesophytes Affect BiomechanicalFunction in Adults With X-linked Hypophosphatemia. J Clin EndocrinolMetab (2020) 105(4):e1798–814. doi: 10.1210/clinem/dgaa064
RIZIV/INAMI. Voor welke zware aandoeningen geniet uw patiënt van een voorkeurstarief voor zijn kinesitherapie behandeling? (2020). Available at: https://www.riziv.fgov.be/nl/professionals/individuelezorgverleners/kinesitherapeuten/Paginas/zware-aandoeningen-lijst-minder-betalen.aspx.
Seikaly MG, Waber PG, Baum M. Urinary prostaglandins and the effect of indomethacin on phosphate excretion in children with hypophosphatemic rickets. Pediatr Res (2008) 64(2):210–2. doi: 10.1203/PDR.0b013e318175d788
Mäkitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab (2003) 88(8):3591–7. doi: 10.1210/jc.2003-030036
Chaussain-Miller C, Sinding C, Wolikow M, Lasfargues JJ, Godeau G, Garabedian M. Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D. J Pediatr (2003) 142(3):324–31. doi: 10.1067/mpd.2003.119
Chaussain-Miller C, Sinding C, Septier D, Wolikow M, Goldberg M, Garabedian M. Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. Oral Dis (2007) 13(5):482–9. doi: 10.1111/j.1601-0825.2006.01326.x
Biosse Duplan M, Coyac BR, Bardet C, Zadikian C, Rothenbuhler A, Kamenicky P, et al. Phosphate and Vitamin D Prevent Periodontitis in X-Linked Hypophosphatemia. J Dent Res (2017) 96(4):388–95. doi: 10.1177/0022034516677528
Connor J, Olear EA, Insogna KL, Katz L, Baker S, Kaur R, et al. Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease. J Clin Endocrinol Metab (2015) 100(10):3625–32. doi: 10.1210/JC.2015-2199
Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab (1992) 75(3):879–85. doi: 10.1210/jcem.75.3.1517380
Suzuki E, Yamada M, Ariyasu D, Izawa M, Miyamoto J, Koto S, et al. Patients with Hypophosphatemic Osteomalacia Need Continuous Treatment during Adulthood. Clin Pediatr Endocrinol (2009) 18(1):29–33. doi: 10.1297/cpe.18.29
Glorieux FH, Marie PJ, Pettifor JM, Delvin EE. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med (1980) 303(18):1023–31. doi: 10.1056/NEJM198010303031802
Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest (1985) 75(6):1858–68. doi: 10.1172/JCI111900
Costa T, Marie PJ, Scriver CR, Cole DE, Reade TM, Nogrady B, et al. X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J Clin Endocrinol Metab (1981) 52(3):463–72. doi: 10.1210/jcem-52-3-463
Martins JS, Liu ES, Sneddon WB, Friedman PA, Demay MB. 1,25-Dihydroxyvitamin D Maintains Brush Border Membrane NaPi2a and Attenuates Phosphaturia in Hyp Mice. Endocrinology (2019) 160(10):2204–14. doi: 10.1210/en.2019-00186
Liu ES, Martins JS, Raimann A, Chae BT, Brooks DJ, Jorgetti V, et al. 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression. J Bone Miner Res (2016) 31(5):929–39. doi: 10.1002/jbmr.2783
Barratt KR, Sawyer RK, Atkins GJ, St-Arnaud R, Anderson PH. Vitamin D supplementation improves bone mineralisation independent of dietary phosphate in male X-linked hypophosphatemic (Hyp) mice. Bone (2020) 115767. doi: 10.1016/j.bone.2020.115767
Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med (1991) 325(26):1843–8. doi: 10.1056/NEJM199112263252604
Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Med (Baltimore) (1989) 68(6):336–52. doi: 10.1097/00005792-198911000-00002
Reade TM, Scriver CR. Hypophosphatemic rickets and breast milk. N Engl J Med (1979) 300(24):1397. doi: 10.1056/NEJM197906143002415
Jonas AJ, Dominguez B. Low breast milk phosphorus concentration in familial hypophosphatemia. J Pediatr Gastroenterol Nutr (1989) 8(4):541–3. doi: 10.1097/00005176-198905000-00021
Ma Y, Samaraweera M, Cooke-Hubley S, Kirby BJ, Karaplis AC, Lanske B, et al. Neither absence nor excess of FGF23 disturbs murine fetal-placental phosphorus homeostasis or prenatal skeletal development and mineralization. Endocrinology (2014) 155(5):1596–605. doi: 10.1210/en.2013-2061
Delzer PR, Meyer RA, Jr. Normal milk composition in lactating X-linked hypophosphatemic mice despite continued hypophosphatemia. Calcif Tissue Int (1983) 35(6):750–4. doi: 10.1007/BF02405118
Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest (2014) 124(4):1587–97. doi: 10.1172/JCI72829
Carpenter TO, Whyte MP, Imel EA, Boot AM, Hogler W, Linglart A, et al. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med (2018) 378(21):1987–98. doi: 10.1056/NEJMoa1714641
Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, et al. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol (2019) 7(3):189–99. doi: 10.1016/S2213-8587(18)30338-3
Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet (2019) 393(10189):2416–27. doi: 10.1016/S0140-6736(19)30654-3
Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM, Nilsson O, et al. Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcif Tissue Int (2021). doi: 10.1007/s00223-020-00797-x
Insogna KL, Briot K, Imel EA, Kamenicky P, Ruppe MD, Portale AA, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res (2018) 33(8):1383–93. doi: 10.1002/jbmr.3475
Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, et al. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcif Tissue Int (2019) 105(3):271–84. doi: 10.1007/s00223-019-00568-3
Insogna KL, Rauch F, Kamenicky P, Ito N, Kubota T, Nakamura A, et al. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial. J Bone Miner Res (2019) 34(12):2183–91. doi: 10.1002/jbmr.3843
Zivicnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R, et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab (2011) 96(12):E2097–105. doi: 10.1210/jc.2011-0399
Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr (2001) 138(2):236–43. doi: 10.1067/mpd.2001.108955
Mäkitie O, Toiviainen-Salo S, Marttinen E, Kaitila I, Sochett E, Sipila I. Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets. Horm Res (2008) 69(4):212–20. doi: 10.1159/000113021
Meyerhoff N, Haffner D, Staude H, Wuhl E, Marx M, Beetz R, et al. Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets. Pediatr Nephrol (2018) 33(3):447–56. doi: 10.1007/s00467-017-3820-3
Rothenbuhler A, Esterle L, Gueorguieva I, Salles JP, Mignot B, Colle M, et al. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). Growth Horm IGF Res (2017) 36:11–5. doi: 10.1016/j.ghir.2017.08.001
Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect (2014) 3(1):R13–30. doi: 10.1530/EC-13-0103
Saggese G, Baroncelli GI, Bertelloni S, Perri G. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density. J Pediatr (1995) 127(3):395–402. doi: 10.1016/S0022-3476(95)70070-6
Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol (2008) 3(3):658–64. doi: 10.2215/CJN.04981107
Raeder H, Shaw N, Netelenbos C, Bjerknes R. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. Eur J Endocrinol (2008) 159(Suppl 1):S101–5. doi: 10.1530/EJE-08-0383
Seikaly MG, Baum M. Thiazide diuretics arrest the progression of nephrocalcinosis in children with X-linked hypophosphatemia. Pediatrics (2001) 108(1):E6. doi: 10.1542/peds.108.1.e6
Seikaly MG, Quigley R, Baum M. Effect of dipyridamole on serum and urinary phosphate in X-linked hypophosphatemia. Pediatr Nephrol (2000) 15(1-2):57–9. doi: 10.1007/s004670000425
Carpenter KA, Ross RD. Sclerostin Antibody Treatment Increases Bone Mass and Normalizes Circulating Phosphate Levels in Growing Hyp Mice. J Bone Miner Res (2020) 35(3):596–607. doi: 10.1002/jbmr.3923
Hoac B, Ostergaard M, Wittig NK, Boukpessi T, Buss DJ, Chaussain C, et al. Genetic Ablation of Osteopontin in Osteomalacic Hyp Mice PartiallyRescues the Deficient Mineralization Without Correcting Hypophosphatemia. J Bone Miner Res (2020) 35(10):2032–48. doi: 10.1002/jbmr.4101
Fratzl-Zelman N, Gamsjaeger S, Blouin S, Kocijan R, Plasenzotti P, Rokidi S, et al. Alterations of bone material properties in adult patients with X-linked hypophosphatemia (XLH). J Struct Biol (2020) 211(3):107556. doi: 10.1016/j.jsb.2020.107556
Cundy T, Que L, Hassan IM, Hughes L. Bisphosphonate-Induced Deterioration of Osteomalacia in Undiagnosed Adult Fanconi Syndrome. JBMR Plus (2020) 4(8):e10374. doi: 10.1002/jbm4.10374
Li J, Rai S, Ze R, Tang X, Liu R, Hong P. Rotational and translational osteotomy for treatment of severe deformity in hypophosphatemic rickets: A case report. Med (Baltimore) (2020) 99(3):e18425. doi: 10.1097/MD.0000000000018425
Sharkey MS, Grunseich K, Carpenter TO. Contemporary Medical and Surgical Management of X-linked Hypophosphatemic Rickets. J Am Acad Orthop Surg (2015) 23(7):433–42. doi: 10.5435/JAAOS-D-14-00082
Horn A, Wright J, Bockenhauer D, Van’t Hoff W, Eastwood DM. The orthopaedic management of lower limb deformity in hypophosphataemic rickets. J Child Orthop (2017) 11(4):298–305. doi: 10.1302/1863-2548.11.170003
Popkov A, Aranovich A, Popkov D. Results of deformity correction in children with X-linked hereditary hypophosphatemic rickets by external fixation or combined technique. Int Orthop (2015) 39(12):2423–31. doi: 10.1007/s00264-015-2814-7
Gizard A, Rothenbuhler A, Pejin Z, Finidori G, Glorion C, de Billy B, et al. Outcomes of orthopedic surgery in a cohort of 49 patients with X-linked hypophosphatemic rickets (XLHR). Endocr Connect (2017) 6(8):566–73. doi: 10.1530/EC-17-0154
Vega RA, Opalak C, Harshbarger RJ, Fearon JA, Ritter AM, Collins JJ, et al. Hypophosphatemic rickets and craniosynostosis: a multicenter case series. J Neurosurg Pediatr (2016) 17(6):694–700. doi: 10.3171/2015.10.PEDS15273
Rothenbuhler A, Fadel N, Debza Y, Bacchetta J, Diallo MT, Adamsbaum C, et al. High Incidence of Cranial Synostosis and Chiari I Malformation in Children With X-Linked Hypophosphatemic Rickets (XLHR). J Bone Miner Res (2019) 34(3):490–6. doi: 10.1002/jbmr.3614
Soehle M, Casey AT. Cervical spinal cord compression attributable to a calcified intervertebral disc in a patient with X-linked hypophosphatemic rickets: case report and review of the literature. Neurosurgery (2002) 51(1):239–42; discussion 42-3. doi: 10.1097/00006123-200207000-00038
Shiba M, Mizuno M, Kuraishi K, Suzuki H. Cervical ossification of posterior longitudinal ligament in x-linked hypophosphatemic rickets revealing homogeneously increased vertebral bone density. Asian Spine J (2015) 9(1):106–9. doi: 10.4184/asj.2015.9.1.106
Riccio AR, Entezami P, Giuffrida A, Dowling J, Forrest G, German JW. Minimally Invasive Surgical Management of Thoracic Ossification of the Ligamentum Flavum Associated with X-linked Hypophosphatemia. World Neurosurg (2016) 94:580 e5– e10. doi: 10.1016/j.wneu.2016.07.076
Nakagawa K, Galati AN. Ultra-early onset of ossification of the posterior longitudinal ligament with congenital rickets. Neurology (2016) 87(16):1738–40. doi: 10.1212/WNL.0000000000003237
Mäkitie O, Kooh SW, Sochett E. Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol (Oxf) (2003) 58(2):163–8. doi: 10.1046/j.1365-2265.2003.01685.x
Mickute G, Staley K, Delaney H, Gardiner O, Hunter A, Keen R, et al. Rare musculoskeletal diseases in adults: a research priority settingpartnership with the James Lind Alliance. Orphanet J Rare Dis (2020) 15(1):117. doi: 10.1186/s13023-020-01398-5
